Redefining recovery for substance use disorders

Tempero Bio is a clinical-stage biopharmaceutical company developing innovative therapeutic solutions for substance use disorders. Their lead candidate, TMP-301, is a metabotropic glutamate receptor 5 (mGluR5) modulator targeting alcohol, stimulant, and opioid use disorders. Formed by Aditum Bio - a biotech VC firm co-founded by Novartis CEO Joe Jimenez and former President of the Novartis Institutes for Biomedical Research Dr. Mark Fishman - Tempero’s leadership leverages decades of addiction and drug development expertise.